Postoperative Malignant Hyperthermia

Authors:

Abstract
MALIGNANT hyperthermia (MH) may occur when a patient with an inherited MH-susceptible mutation is exposed to one or both types of anesthetic triggering agents (i.e. , volatile inhalational agents and succinylcholine). In most reported cases, signs and symptoms consistent with the hypermetabolic nature of MH have occurred during administration of the triggering agent. However, there are some reported cases in which the onset of MH began in the postoperative period. The definitive latency period between the discontinuation of an anesthetic triggering agent and the beginning of the manifestations of MH varies from case to case, but the maximal latency period is unknown. Therefore, the aim of this study was to define these latency periods and to describe the clinical characteristics of patients in whom signs and symptoms of acute MH began in the postoperative period, by using a database of suspected MH episodes in patients included in the North American Malignant Hyperthermia Registry (NAMHR). Furthermore, we examined the existing published cases of postoperative MH in an attempt to lend clarity to these cases using current knowledge regarding the clinical and pathophysiologic aspects of MH. Based on our review of the existing literature and our experience as MH hotline consultants, we hypothesized that postoperative MH represents a small overall fraction of existing MH cases and usually is identified in the early postoperative period.

This publication has 19 references indexed in Scilit: